-
Baekje Shenzhou Introduces Onsen Pharmaceuticals CDK2 Inhibitors for $1.33 billion
On November 21st, Baekje announced that it had reached a cooperation agreement with Ensem Therapeutics to introduce the CDK2 inhibitor ETX-197, which the latter is about to submit for IND (drug clini ... -
New indications for BeiGene PD-1 inhibitor for first-line treatment of hepatocellular carcinoma
On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China f ... -
MSD PD-1 inhibitor approved by the US FDA
On January 12th local time, Merck announced that the US Food and Drug Administration (FDA) has approved the use of Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (C ... -
Mercado PD-1 inhibitor approved by the US FDA for the treatment of cervical cancer patients
On January 14th, Merck announced on January 12th local time that the US Food and Drug Administration (FDA) has approved Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemothera ... -
JAK1 inhibitor Xibico? New indications for age expansion approved in China
Southern Finance and Economics, March 4th - Today, Pfizer announced that it is a highly selective JAK1 inhibitor and an innovative oral small molecule targeted drug called Xibico; Reg; The new indica ... -
Merck PD-1 inhibitor CRDA approved as a new indication for melanoma treatment in China
On September 14th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment ... -
Lilly: The first and only non covalent (reversible) BTK inhibitor, Jeparil, has been approved in China
On October 30th, Eli Lilly China announced that its non covalent (reversible) BTK inhibitor, Jepanib (100mg and 50mg tablets of Pitobutinib), has been approved by the National Medical Products Admini ... -
Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
On December 3rd, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) We have obtained approval from the National Medical Products Administration (NMPA) of China to combine p ... -
Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
Merck announced that its PD-1 inhibitor pembrolizumab (trade name: pembrolizumab) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of locally advanc ... -
Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
On December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) Approved by the National Medical Products Administration (NMPA) of China, the combination of radiothera ... -
Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
According to AI News, on December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA& reg;) Approved by the National Medical Products Administration (NMPA) of China, the co ... -
Sanofi's BTK inhibitor is declared for market in China
New Beijing News (Reporter Zhang Zhaohui) On December 30th, the official website of the Drug Evaluation Center of the National Medical Products Administration announced that the application for the l ...